Company profile CMMB
There is not enough data for chemomab therapeutics -stock to provide analysis
There is not enough data for chemomab therapeutics -stock to provide correlation calculation
There is not enough data for chemomab therapeutics -stock to provide analysis
There is not enough data for chemomab therapeutics cm-101 to provide analysis
There is not enough data for chemomab therapeutics cm-101 to provide correlation calculation
There is not enough data for chemomab therapeutics cm-101 to provide analysis
There is not enough data for chemomab therapeutics clinical trials to provide analysis
There is not enough data for chemomab therapeutics clinical trials to provide correlation calculation
There is not enough data for chemomab therapeutics clinical trials to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. primary sclerosing cholangitis treatment expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 139 | 218 56.8% QoQ | 120 -45.0% QoQ | 97 -19.2% QoQ |
| 2020 | 190 36.7% YoY 95.9% QoQ | 58 -73.4% YoY -69.5% QoQ | 112 -6.7% YoY 93.1% QoQ | 71 -26.8% YoY -36.6% QoQ |
| 2021 | 106 -44.2% YoY 49.3% QoQ | 243 319.0% YoY 129.2% QoQ | 58 -48.2% YoY -76.1% QoQ | 159 123.9% YoY 174.1% QoQ |
| 2022 | 24 -77.4% YoY -84.9% QoQ | 112 -53.9% YoY 366.7% QoQ | 148 155.2% YoY 32.1% QoQ | 148 -6.9% YoY 0.0% QoQ |
| 2023 | 51 112.5% YoY -65.5% QoQ | 134 19.6% YoY 162.7% QoQ | 219 48.0% YoY 63.4% QoQ | 147 -0.7% YoY -32.9% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of primary sclerosing cholangitis treatment was 9.79 per week. The last year interest of primary sclerosing cholangitis treatment compared to the last 5 years has changed by 8.27%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -10.55%.
After 39 days of this quarter the interest is at 40.0. Based on that we can calculate that during remaining 52 days it will total up to 93.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 59 | 141 139.0% QoQ | 43 -69.5% QoQ | 90 109.3% QoQ |
| 2020 | 132 123.7% YoY 46.7% QoQ | 37 -73.8% YoY -72.0% QoQ | 100 132.6% YoY 170.3% QoQ | 26 -71.1% YoY -74.0% QoQ |
| 2021 | 103 -22.0% YoY 296.2% QoQ | 104 181.1% YoY 1.0% QoQ | 123 23.0% YoY 18.3% QoQ | 81 211.5% YoY -34.1% QoQ |
| 2022 | 44 -57.3% YoY -45.7% QoQ | 89 -14.4% YoY 102.3% QoQ | 158 28.5% YoY 77.5% QoQ | 19 -76.5% YoY -88.0% QoQ |
| 2023 | 122 177.3% YoY 542.1% QoQ | 111 24.7% YoY -9.0% QoQ | 175 10.8% YoY 57.7% QoQ | 103 442.1% YoY -41.1% QoQ |
| 2024 | 40 -67.2% YoY -61.2% QoQ | - | - | - |
The average 5 years interest of systemic sclerosis treatment was 7.28 per week. The last year interest of systemic sclerosis treatment compared to the last 5 years has changed by 35.03%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 20.02%.
There is not enough data for fibrotic diseases treatment to provide analysis
There is not enough data for fibrotic diseases treatment to provide correlation calculation
There is not enough data for fibrotic diseases treatment to provide analysis
There is not enough data for inflammatory diseases treatment to provide analysis
There is not enough data for inflammatory diseases treatment to provide correlation calculation
There is not enough data for inflammatory diseases treatment to provide analysis
After 39 days of this quarter the interest is at 100.0. Based on that we can calculate that during remaining 52 days it will total up to 233.0. chemomab therapeutics news expected interest is significantly higher compared to previous quarter (+210.7%) and same quarter last year (+331.5%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 32 | 66 106.2% QoQ | 0 -100.0% QoQ | 12 inf% QoQ |
| 2020 | 37 15.6% YoY 208.3% QoQ | 0 -100.0% YoY -100.0% QoQ | 20 inf% YoY inf% QoQ | 8 -33.3% YoY -60.0% QoQ |
| 2021 | 29 -21.6% YoY 262.5% QoQ | 41 inf% YoY 41.4% QoQ | 23 15.0% YoY -43.9% QoQ | 10 25.0% YoY -56.5% QoQ |
| 2022 | 12 -58.6% YoY 20.0% QoQ | 18 -56.1% YoY 50.0% QoQ | 30 30.4% YoY 66.7% QoQ | 52 420.0% YoY 73.3% QoQ |
| 2023 | 54 350.0% YoY 3.8% QoQ | 18 0.0% YoY -66.7% QoQ | 40 33.3% YoY 122.2% QoQ | 75 44.2% YoY 87.5% QoQ |
| 2024 | 100 85.2% YoY 33.3% QoQ | - | - | - |
The average 5 years interest of chemomab therapeutics news was 2.59 per week. The last year interest of chemomab therapeutics news compared to the last 5 years has changed by 113.13%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 117.32%.